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Identity 
Other names: ARCC2, CTPA, CTPP1, ECK 
HGNC (Hugo): EPHA2 
Location: 1p36.13 
Note 
EPHA2 was identified in 1990 by the screening of 
human epithelial cells (HeLa cells) cDNA library using 
degenerate probes designed to hybridize to highly 
conserved regions of protein tyrosine kinases. EPHA2 
was initially referred to as Eck (epithelial cell kinase) 
for its expression in the majority of epithelial cels. 
DNA/RNA 
Description 
The EPHA2 is composed of 17 exons and 16 
intervening introns spanning in a region of 31,73 kb. 
Transcription 
The transcribed mRNA was 3970 bp (NM_004431). 
 
EPHA2 gene structure. This diagram presents exon as blue boxes, introns as connecting lines with bp, codons are numbered in pink 
boxes and the location of structural motifs of EPHA2 protein as yellow boxes. 
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EPHA2 receptor is a transmembrane glycoprotein 
composed of 976 amino acid residues, with a calculated 
molecular mass of 130 kDa and an isoelectric point 
6.1398. It is one member of the largest EPH 
(erythropoietin-producing hepatoma amplified 
sequence) family receptor tyrosine kinases. The family 
of Eph kinases binds ligands (known as ephrins) that 
are anchored to the membrane adjacent cells and 
consists of 16 known members across species, 14 of 
which are found in mammals and characterized by 
shared features in both the extracellular and 
intracellular domains. 
EPH class receptors contain a single transmembrane 
spanning domain. Like other receptor tyrosine kinases, 
the extracellular domain of EPHA2 mediates ligand 
binding whereas the intacellular domain possesses 
intrinsic enzymatic activity. 
The extracellular domain is glycosylated and is 
composed of globular, amino terminal domain followed 
by a cysteine-rich region with an epidermal growth 
factor-like motif and two fibronectin III-type repeats. 
The globular, amino-terminal domain contains 
immunoglobulin-like motifs and is both necessary and 
sufficient for ephrin-binding. 
The intracellular domain includes a juxtamembrane 
region, a tyrosine kinase domain, a sterile alpha motif 
(SAM) and a PDZ-binding motif in the carboxy 
terminal end. The kinase domain and juxtamembrane 
region contain tyrosine residues and phosphorylation of 
these tyrosine residues creates docking sites for 
interaction with signalling proteins containing 
SH2/SH3 (Src - homology - 2/3) domains. SAM 
domain forms homodimers and may regulate receptor 
dimerization. The PDZ-binding motif binds to PDZ  
domain-containing proteins, which are though to serve 
as scaffolds for the assembly of multi-protein signalli g 
complexes at the membrane. 
EPHA2 shows 25-35% sequence homologies with 
other EPH receptors, and the tyrosine residues are 
conserved within the juxtamembrane and kinase 
domain. 
Expression 
EPHA2 is largely restricted at low levels on adult 
proliferating epithelial cells and enriched within sites of 
cell-cell adhesion in normal epithelial cells. EPHA2 
expression has been detected in the brain, skin, boe 
marrow, lung, thymus, small intestine, colon, urinay 
bladder, kidney, liver, spleen, uterus, testis and 
prostate. EPHA2 expression levels in the colon, skin, 
kidney and lung were over 10-fold compared to those 
of the bone marrow. EPHA2 is also expressed during 
gastrulation in the ectodermal cells and early 
embryogenesis in the developing hind brain. In the 
skin, EphA2 is present in keratinocytes of epidermis 
and hair follicles but not in dermal cells, such as 
fibroblasts, vascular cells and inflammatory cells. 
EPHA2 has also been detected in proliferating 
mammary glands in female mice at puberty and 
differentially expressed during the estrous cycle. 
EPHA2 is widely unregulated and functionally altered 
in a variety of carcinomas and is implicated in cell 
transformation, primary tumor initiation, angiogenesis 
and metastasis in advanced cancer models. 
Overexpression has been shown both at the mRNA and 
protein level in established cell lines and human 
clinical specimens. Consistent findings indicate the 
prevalence of EPHA2 overexpression in many cancers, 
including glioblastoma, colorectal, gastric, esophageal, 
breast, thyroid, ovarian, endometrial, cervical, 
pancreatic, prostate, melanoma, bladder, renal cell, 
lung and hepatocellular carcinoma. 
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Localisation 
The EPHA2 is localized to the cell membrane. 
Function 
The ligands for the EPH receptors are ephrins, which 
are 9 members and also fall into 2 subclasses: the GPI 
(glycosylphosphatidylinositol) anchored A-class of 
ligands (Ephrin A1-6) and the transmembrane B-class 
of ligands (B1-3). 
EPH receptors interact with their cognate membrane 
anchored ligands at cell-cell contact sites to activ te 
bidirectional signaling pathways effecting diverse 
physiologic processes including cell adhesion, 
repulsion, morphology, migration, differentiation ad 
proliferation. Specifically, EPHA2 is activated by the 
ligand ephrin A1/EFNA1 and regulates migration, 
proliferation, integrin-mediated adhesion and 
differentiation of cells. 
EPH receptor signaling has been implicated in many 
biological processes such as axon guidance and 
fasciculation, tissue border formation, neuronal 
targeting and angiogenesis during embryonic 
development. Especially, EPHA2 is involved in 
angiogenesis, in early hindbrain development and 
epithelial proliferation and branching morphogenesis 
during mammary gland development. EPHA2 with 
ephrin A2/EFNA2 may play a role in bone remodeling 
through regulation of osteoclastogenesis and 
osteoblastogenesis. It also engaged with the ephrin 
A5/EFNA5 and may regulate lens fiber cells shape and 
interactions and be critical for lens transparency 
development and maintenance. 
Emerging evidence implicates EPHA2 overexpression 
in cell transformation, primary tumor initiation, 
progression, angiogenesis and metastasis in a variety of 
cancer models. 
Homology 
Human EPHA2 shares 96% amino acid identity with 
the chimpanzee, 95% amino acid identity with dogs, 
94% with cows, 93% with mouse, 92% with rats and 
56% amino acid identity with zebrafish. 
Mutations 
Note 
Congenital cataract (CC) is one of the most significant 
causes of visual impairment and blidness in childhood. 
Approximately, up to 25% of all CC could be inheritd, 
most often transmitting as an autosomal dominant trait 
and showing considerable inter- and intra-familial 
phenotypic variation. 
Germinal 
Loci for autosomal dominant posterior polar CC and 
total CC have both been mapped to chromosom 1p36 
harboring the EPHA2 gene. Two missense mutations 
and one frameshift in the EPHA2 gene have been 
linked with posterior polar CC and one splicing 
mutation have been associated with total CC.  
The c.2819 C>T (p.T940I) missense mutation changes 
an oligomerization interface of the SAM domain, most 
likely inactivating the EPHA2 signalling function by 
destroying its SAM domain. 
The c.2842 G>T (p.G648W) missense mutation 
identified in exon 17 and occured at the first base of 
codon 948 and was predicted to result in substitution of 
glycine to tryptophan at the level of translation, placing 
it in the cytoplasmic SAM domain of EPHA2 gene. 
The c.2915_2916delTG deletion of 2 bp discovered in 
exon 7 of EPHA2 gene and was predicted to result in a 
frameshift mutation creating a mutant protein with a 
novel C-terminal polypeptide of 39 amino acid 
residues. 
The c.2826-9G>A is a splicing mutation with a single 
base substitution in intron 16 which creates a novel 
splice acceptor site causing an intronic sequence of 7 
bp to be included in the processed transcript. This 
aberrant splicing is predicted to result in translational of 
a novel C-terminal polypeptide of 71 amino acid 
residues of which the last 39 are identical to thatof the 




EphA2 has been reported to be overexpressed in 
several cancers and a high level of EphA2 has been 
detected in malignant cancer-derived cell lines and 
advanced forms of cancer. 
Prognosis 
Eph-A2 overexpression was significantly associated 
with poor prognosis in several types of malignant 
tumors, including oral tongue, oesophageal, lung, renal, 
ovarian, cervical and endometrial carcinoma, as well as 
glioblastoma and melanoma. In human epidermal 
growth factor receptor 2 (Her2) positive breast cancer 
patients, increased levels of EphA2 mRNA were 
correlated to a decreased potential for overall and 
disease-free survival. 
Epithelial ovarian carcinoma 
Note 
High EphA2 expression was evident in clinical 
specimens of invasive ovarian tumors, while little or no 
staining was observed in normal ovaries. Moreover, 
EphA2 overexpression was significantly associated 
with higher grade, advanced disease stage and with 
factors involved in invasion and angiogenesis. A 
relationship between EphA2 overexpression and the 
status of tumor suppressor p53 was noted. High EphA2 
expressing tumors exhibited increased microvessel 
density when stained for CD31 as a measure of 
angiogenesis. In addition, the matrix metalloproteinase  
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expression, which degrades the extracellular matrix 




In clinical prostate carcinoma specimens, EphA2 
immunoreactivity was increased with a positive 
staining in 60-100% of cells. EphA2 was overexpressed 
more in metastatic cells compared to non-invasive 
prostatic epithelial cells and its levels as increased as 




In breast carcinoma specimens, 92% of the cases 
showed moderate to high staining for EphA2. EphA2 
overexpression in breast cancer was negatively 
associated with estrogen receptor expression. In clinica  
specimens of benign mammary epithelia, 75% of the 




EphA2 was overexpressed in about 95% of pancreatic 
cancer specimens, being associated with metastatic 




In non-small cell lung cancer specimens, moderate to 
high EphA2 immunostaining was observed in the 
membrane and cytoplasm in more than 70% of the 
examined carcinomas. This increase was comparable in 
adenocarcinoma, squamous cell carcinoma and large 
cell carcinomas. EphA2 was also associated with 
clinically advanced stages of disease, the presence of 
brain metastasis and smoking status. 
Brain cancers 
Note 
EphA2 was found to be overexpressed but not to be 
tyrosine phosphorylated in glioblastoma multiforme 
cells or tumors. In surgically resected human malign nt 
glioma tissues, a heterogeneous and variable EphA2 
staining pattern was observed. Although normal brain 
tissues exhibited minimal EphA2 staining, the cases of 
anaplastic astrocytoma and glioblastoma multiforme 
exhibited variable staining patterns. In astrocytic 
tumors, EphA2 overexpression was also correlated with 
the pathological grade and the proliferation status of 
tumors. 
Urinary bladder carcinoma 
Note 
Clinical specimens of urinary bladder carcinoma when  
examined by a semi-quantitative immunostaining 
showed a differential staining pattern than normal 
specimens. Of all urinary bladder specimens with Ta 
grade lesions, 30% showed moderately strong staining, 
while in the T3 and T4 lesions, 75% and 90% of the 
samples showed strong staining, respectively. In sharp 
contrast, 85% of normal tissues showed weak staining, 
while the remaining 15% showed moderate staining for 
EphA2. Notably, EphA2 staining intensity was 
associated with advanced stage of urothelial carcinoma. 
Melanoma 
Note 
EphA2 was found to be phosphorylated in aggressive 
melanoma-derived cells and was associated with 
vasculogenic mimicry, i.e. the formation of endothelial 
cell-like network. In a tissue microarray of melanomas, 
strong cytoplasmic EphA2 staining was present in 16% 
of the cases, being associated with histological 
thickness of melanomas and tumors proliferation statu . 
A correlation of metastatic potential and high EphA2 
expression was also observed in human melanoma cell 
lines derived from patients, while EphA2 
overexpression changed cellular migration from the 
mesenchymal- to the amoeboid-type. 
Oesophageal squamous cell carcinoma 
Note 
EphA2 overexpression was detected in esophageal 
carcinoma-derived cells and in 50% of clinical 
specimens. EphA2 expression was correlated with 
lymph node metastases, whereas no significant 
association with patients' age, tumour location, tumo r 




Increased expression of EphA2 was observed in over 
59% of clinical specimens from colorectal cancer 
patients. EphA2 expression was increased in early-
stage tumors compared to those of advanced stage, as 
well as in smaller tumors than large tumors. 
Microvessel count was also correlated with 
overexpression of EphA2. In human colon cancer-
derived HCT116 cells, a dose and time-dependent 
upregulation of EphA2 was noticed after treatment with 
deoxycholic acid, a component of bile acids and 
promoter of colon cancer. The upregulation of EphA2 
was p53-independent, but it was linked to the activtion 
of MAP kinase pathway. 
Renal cell carcinoma 
Note 
Higher levels of EphA2 expression were correlated 
with tumors that were of higher grade, larger and more 
highly vascularized in patients with renal cell 
carcinoma. 
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Vulvar carcinoma 
Note 
In vulvar cancers, more than 50% of vulvar squamous 
cell carcinomas expressed elevated levels of EphA2. 
Malignant and benign thyroid 
malignancies 
Note 
Eph-A2 receptor was associated with increased 
proliferative activity of malignant thyroid lesions. Eph-
A2 was significantly overexpressed in malignant 
compared to benign thyroid lesions. Papillary 
carcinoma cases also presented significantly increased 
Eph-A2 expression compared to those with hyperplasia 
nodules. 
Squamous cell cervical carcinomas 
Note 
In early squamous cell cervical carcinomas, EphA2 
expression was classified as negative in 21 tumors 
(10%), weak positive in 108 tumors (50%), moderate 
positive in 69 (32%) and strong positive in 19 tumors 
(9%). 
Oral tongue squamous cell carcinoma 
Note 
In oral tongue SCC specimens, Eph-A2 expression was 
significantly correlated with tumor size, clinical stage, 
lymph invasion, recurrence and distant metastasis. 
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